EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective
Abstract
Authors
T. Senna R.F. Alexandre P. Almeida M. Sebastião P. Ferreira